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Abstract Chronic treatment with oral levodopa is asso-
ciated with an increased frequency of motor complications
in the late stages of Parkinson’s disease (PD). Continuous
administration of levodopa–carbidopa intestinal gel
(LCIG—Duodopa, Abbott Laboratories), which has been
available in Romania since 2009, represents an option for
treating patients with advanced PD. Our primary objective
was to report changes in motor complications after initiation
of LCIG therapy. The secondary objectives were as follows:
to determine the impact of LCIG therapy on the daily
levodopa dose variation before/and after LCIG, to collect
patient self-assessments of quality of life (QoL), and to
study the overall tolerability and safety of LCIG adminis-
tration. A retrospective analysis (2009–2013) of LCIG
therapy and the experience in nine neurology centers in
Romania was performed. The impact of LCIG therapy was
evaluated by analyzing changes in motor fluctuations,
dyskinesia and the patients’ QoL after initiating therapy.
The safety of LCIG therapy was estimated by noting agent-
related adverse events (AEs) and medical device-related
AEs. In the 113 patients included, we observed a significant
improvement in PD symptoms after initiation of LCIG
therapy. The ‘‘on’’ period increased, with a mean value of
6.14 h, and the dyskinesia period was reduced, with a mean
value of 29.4 %. The quantified non-motor symptoms
subsided. The patients exhibited significant improvements
in QoL scores. There were few AEs and few cases of LCIG
therapy discontinuation. LCIG is an important and available
therapeutic option for managing patients with advanced PD.
Keywords Parkinson’s disease  Motor complications 
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Introduction
Levodopa is currently the most effective agent for symp-
tomatic treatment of PD, particularly when bradykinetic
symptoms become intrusive with respect to a patient’s
motor abilities. However, while the exact percentage is
difficult to estimate (Ahlskog and Muenter 2001), some-
where between 50 and 90 % of patients with PD develop
motor complications and dyskinesia within 5–10 years of
levodopa treatment (Olanow et al. 2001). Dyskinesia, the
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most invalidating side effect of oral L-dopa therapy,
becomes increasingly frequent with long-term treatment
and advanced disease and is one of the greatest disadvan-
tages of the oral levodopa treatment for Parkinson’s dis-
ease. As the therapeutic window becomes narrower, fine-
tuning between the ‘‘off’’ time and dyskinesia becomes
more difficult with the use of oral therapies partly because
the gastric passage severely interferes with the process.
Furthermore, motor fluctuations represent the other end of
the problem, also highlighting the relatively short half-life
of levodopa. Therefore, these side-effects of levodopa
therapy are likely due to both the pulsatile dopaminergic
substitution pharmacological characteristics of all available
oral levodopa formulations (immediate or extended
release) and the potential gastric barrier to its absorption.
Continuous administration of LCIG through intestinal
infusion represents a therapeutic option for advanced PD.
Studies have demonstrated that the levodopa plasma con-
centration is less time variable with LCIG than with tablets
(Nyholm et al. 2003). Data regarding its effects have been
systematically collected in countries in which LCIG has
been approved for use in routine clinical practice.
This therapeutic option for managing patients with
advanced PD has been available in Romania since 2009
and has been used ever since in nine tertiary neurology
centers. Other therapeutic options, such as apomorphine
(Poewe and Wenning 2000; Drapier and Ve´rin 2006) and
subthalamic nucleus deep brain stimulation (Krach et al.
2003; Tir et al. 2007), are applicable only to specific
patient populations because of the particular inclusion
criteria, which usually take into account age, degree of
independence, disease stage, complications and co-mor-
bidities (Morgante et al. 2007; Antonini and Tolosa 2009).
In Romania, the availability of deep brain stimulation
surgery is restricted to a single center that receives limited
funding, and apomorphine was not available during the
study period. Therefore, in Romania during the study
period, LCIG therapy was the most optimal and readily
available treatment for patients with advanced PD.
We aimed to establish the therapeutic benefit of this
treatment during the first 5 years of treatment, as quantified by
changes in motor skills and quality of life (QoL) scores. We
collected data regarding all of the safety endpoints, including
administration of medications, percutaneous endoscopic
gastrojejunostomy (PEG/J) procedure and compliance.
Methods
Patient selection
Our study is an open, retrospective observation of the
medical records of all of the patients who received LCIG
(Duodopa, Abbott Laboratories) continuous infusion
therapy via percutaneous endoscopic gastrojejunostomy
(PEG/J) by means of a device (CADD-legacy-Duodopa-
pump, Smiths Medical, MN, USA) at nine neurology
centers in Romania (three centers in Bucharest, two centers
in Cluj and one center in each of Oradea, Targu Mures, Iasi
and Timisoara) from 1 January 2009 until the 30 Septem-
ber 2013. The data collection was approved by the local
ethics committee of each center. All of the patients
underwent a naso-jejunal test to evaluate their response to
continuous administration of LCIG, and they were con-
sidered to be good responders.
Clinical data
The efficacy of this treatment for controlling motor
symptoms was evaluated by analyzing the patients’ diaries,
focusing on the daily length of the ‘‘off’’ period and the
daily percentage of ‘‘on’’ time with dyskinesias. These data
were collected for each patient during oral anti-parkinso-
nian therapy (with levodopa alone or combined with other
oral therapies) to establish a baseline and several months
after LCIG treatment initiation, during a follow-up visit
performed between 3 and 6 months after treatment
initiation.
The patients’ self-evaluation of their QoL before and
after LCIG therapy was measured using the 10-point Visual
Analog Scale (VAS).
Furthermore, quantification of non-motor symptom
variation before and after LCIG therapy was performed
using the information gathered by clinicians at the time that
they evaluated the patients.
Additionally for each patient, we collected the total 24-h
dose of levodopa administered before and during LCIG
therapy.
The overall tolerability and safety of LCIG administra-
tion were evaluated based on the reports of agent-related
AEs and medical device-related AEs collected from the
patients’ medical files.
The levodopa equivalent daily dose (LEDD) was cal-
culated using a formula recommended by the LCIG pro-
vider in Romania, as follows LEDD = levodopa dose ?
levodopa dose\ extended release[90.75 ? levodopa
dose 9 0.33\ if associated with entacapone[?
pramipexole 9 100 ? ropinirole 9 20 ? rotigotine 9
30 ? rasagiline 9 100 ? amantadine).
Statistical analysis
The changes in ‘‘off’’ time and the percentage of time with
dyskinesias before and after LCIG initiation were com-
pared using the Wilcoxon matched pairs signed rank test.
The statistical significance level used 0.05.
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The variables were described using standard statistical
measures (number of observations, mean values, and
minimum and maximum values) or frequency tables.
Results
In our study, we included a total of 113 patients diagnosed
with advanced primary Parkinson’s disease (Hoehn and
Yahr stage C3). There were 31 patients in Bucharest, 14
patients in Cluj, 2 patients in Oradea, 31 patients in Targu
Mures, 19 patients in Iasi and 13 patients in Timisoara.
Females comprised 40 % of the patients and males 60 %.
The mean age was 64 years. The mean duration from the
time of clinical diagnosis of Parkinson’s disease until
LCIG therapy initiation was 12 years. The mean duration
of LCIG therapy was 2.1 years (1–5) (Table 1).
The increasing annual therapy initiation rate is shown in
Fig. 1; the year 2013, which appears to have a lower ini-
tiation rate, was observed only until September. By the end
of the observation period, the number of patients who still
required LCIG treatment was 103.
Benefit of LCIG therapy in terms of motor
symptoms
The duration of the ‘‘off’’ time was significantly less after
LCIG initiation (p\ 0.0001); the comparison was made
between the ‘‘off’’ period while on oral medication at the
screening visit before LCIG therapy initiation and that after
LCIG therapy initiation at a follow-up visit (3–6 months
later). The mean ‘‘off’’ time before LCIG therapy was
7.5 h, whereas after LCIG therapy, it was 1.36 h. Thus, the
mean reduction in the ‘‘off’’ period was 6.14 h.
By providing continuous intrajejunal infusion, LCIG
therapy facilitated better symptom control in our patients,
significantly reducing the percentage of daily dyskinesia,
with a mean of 29.4 % (from a mean of 36.3 % before
LCIG to a mean of 6.9 % after LCIG) after initiation of
LCIG therapy (p\ 0.0001) (Table 1). Figure 2 shows the
dyskinesia percentage before and after LCIG therapy.
The off-time in the male population (68 patients) was
reduced with a mean of 7.03 h (range between 2 and 15 h)
from the mean off-time before LCIG therapy of 8.36 h
(range between 3 and 15 h). In the same subgroup, the
Table 1 General characteristics
of patients
Number of patients 113
Males (number, percent) 68 (60 %)
Females (number, percent) 45 (40 %)
Age at initiation of therapy (median, range) 65 (26–79 years)
Disease duration until LCIG infusion (median, range) 12 (3–35 years)
Dyskinesia before and after LCIG continuous infusion therapy (mean, min–max)
Mean daily percentage of dyskinesia before LCIG 36.31 % (0–75 %)
Mean daily percentage of dyskinesia after LCIG 6.89 % (0–50 %)
Reduction in daily dyskinesia percentage 29.41 %
Levodopa dose before and after LCIG continuous infusion therapy (mean)
Daily Levodopa dose (mg) before LCIG 967.74 mg
Daily Levodopa dose (mg) after LCIG 1570.04 mg
Increase in daily levodopa dose (mg) after LCIG 602.29 mg
QoL assessment with the 10 points VAS before and after LCIG
continuous therapy initiation (mean, min–max)
Score before LCIG initiation 1.97 (0–6)
Score after LCIG initiation 6.8 (2–10)
Increase of the score after LCIG initiation 4.83
Reported adverse events (number, percent)
Total number of patients that reported AEs 58 (51 %)
Patients that had incidental AEs 44 (38.93 %)
Patients that had LCIG infusion therapy-related AEs 15 (13.27 %)
Patients that had dopaminergic therapy-related AEs 7 (6.19 %)
Patients that had LCIG administration system-related AEs 2 (1.76 %)
Patients that had PEG/J procedure-related AEs 3 (2.65 %)
Patients that had compliance-related AEs 3 (2.65 %)
LCIG levodopa–carbidopa intestinal gel, AEs adverse events, PEG/J percutaneous endoscopic jejunostomy
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mean percentage of dyskinesia before LCIG therapy was of
24.98 % (ranging between 0 and 75 %) and this improved
after LCIG therapy with a mean of 17.24 % (ranging
between 0 and 63 %). In the female population (45
patients) the off-time was reduced after LCIG therapy with
a mean of 5.06 h (range between 0 and 9 h), from a mean
of 6.08 h before LCIG therapy (range between 2 and 10 h).
Improvement of dyskinesia daily percentage was with a
mean of 33.2 % (range between 0 and 75 %) from the
situation before LCIG therapy, when the dyskinesia mean
percentage was of 43.44 % (range between 0 and 76 %)
(Table 2).
Furthermore, in the group of patients aged 60 or
younger, the mean reduction of off-time was of 5.7 h
(range between 2 and 15 h), from a mean of 6.51 h spent in
off-time (range between 2 and 15 h) before the LCIG
therapy. They also had a mean reduction of 28.1 % in the
daily dyskinesia percentage (range between 0 and 65 %)
from the mean of 38 % of daily dyskinesias before LCIG
therapy (range between 0 and 86 %).
In the group of patients above the age of 60, the mean
reduction of the off-time was of 6.42 h (range between 0
and 13 h) from a mean of 7.75 h before LCIG therapy
initiation (range between 2 and 13 h). The percentage of
daily dyskinesia improved with a mean of 22.18 % (range
between 0 and 75 %) from a mean of 30.30 % before LCIG
therapy initiation (range between 0 and 75 %). Addition-
ally, Fig. 3 depicts the impact LCIG therapy had on
patients aged 60, or younger, vs. patients older than
60 years of age, respective of gender.
Impact of LCIG therapy on the daily levodopa dose,
before and after LCIG
LCIG continuous infusion therapy allowed an overall
increase of the mean LEDD compared with the mean
LEDD received while on oral therapy (from a mean of
967 mg/day to a mean of 1570 mg/day), with only 18 % of
the patients exhibiting improved symptom control at lower
levodopa doses compared with oral therapy (Table 1). The
LEDD was calculated including all dopaminergic medi-
cation before LCIG therapy initiation.
Twenty patients (17.69 %) were administered an
extended-release levodopa tablet after the LCIG had been
stopped in the evening, and three patients (2.65 %)
required 24-h continuous LCIG therapy because of poor
motor and non-motor symptom control during the night,
with only the conventional anti-parkinsonian therapies,
essentially leading to severe impairment of sleep quality.
Seven patients (6.19 %) received a dopaminergic agonist at
bedtime (rotigotine for one patient, pramipexole for two
patients, ropinirole for two patients, and a combination of
ropinirole and rotigotine for one patient); nine patients
(7.96 %) received an MAO inhibitor in the morning
(rasagiline); and six patients (5.30 %) received amantadine
for persistent dyskinesia.
Patients’ self-assessments of QoL
A marked increase in their perception of their QoL was
observed (Table 1), suggesting that LCIG therapy signifi-
cantly improved the patients’ QoL (p\ 0.01).
Overall tolerability and safety of LCIG
administration
A total of 58 (51 %) of 113 patients reported AEs. Of these
AEs, 15 AEs (13.27 %) were related to LCIG infusion
therapy, as follows: (1) seven AEs (6.19 %) were related to
the medication itself (LCIG), meaning they were common
adverse effects of the dopaminergic substitution therapy;
(2) two AEs (1.76 %) were related to the LCIG adminis-
tration system, meaning patients presented with problems
Fig. 1 Annual therapy initiation rate
Fig. 2 Percentage of daily dyskinesia before and after LCIG therapy
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of the intestinal tubes (calcification of intestinal tube—one
case, detachment of intestinal tube—one case); (3) three
AEs (2.65 %) were related to the PEG/J procedure, that is,
complications secondary to the invasive placement of the
intestinal tubes (post-interventional hiatal herniation—one
case, abdominal wall leiomyoma—one case, sub-phrenic
and hepatic abscess—one case). The rest of the reported
AEs had no apparent relationship with the study treatment
(Table 1). There were five deaths during the study period.
One patient died as a result of the PEG/J procedure
(pneumoperitoneum that resulted in peritonitis, septic
shock and death), and the other four deaths occurred during
the follow-up period (as a result of cardiovascular and
respiratory co-morbidities). In seven patients, the treatment
was ceased (one temporary and six definitive). The dropout
reasons, in the six patients, were as follows: (1) compliance
issues (lack of family support) in one patient; (2) severe
dopaminergic adverse effects and cognitive decline in three
patients (also posing compliance issues); and (3) digestive
tract complications or other severe co-morbidities in two
patients (Fig. 4).
Nine patients had newly diagnosed digestive tract
pathologies during the study period. In one patient, the
occurrence of a duodenal inflammatory reaction of
unknown origin led to treatment cessation. The other
diagnoses were as follows: superior digestive tract hem-
orrhage with melena and secondary anemia, sub-phrenic
abscess, cascade stomach, hiatal herniation with intra-tho-
racic gastric volvulus, neoplasia of the hepatic angle of the
colon, erosive esophagitis, erosive gastritis, and catarrhal
cholecystitis with pancreatitis.
Table 2 Reported non-motor
symptoms
Non-motor symptom Number of patients Percentage ‘‘on’’ period gain after LCIG
Sialorrhea 18 15.92 6.33
Taste disturbance 23 20.35 6.21
Nausea, vomiting 5 4.42 8.4
Constipation 44 38.93 6.7
Urinary incontinence 28 24.77 6.82
Weight loss 7 6.19 5.14
Hallucinations 6 5.3 6.41
Depression 56 49.5 6.43
Sexual dysfunction 11 9.73 6.9
Orthostatic hypotension 7 6.19 6.17
Excessive sleepiness 35 30.97 6.7
Insomnia 41 36.28 6.2
REM sleep disturbances 28 24.7 6.32
Restless legs syndrome 14 12.38 5.53
Excessive sweating 19 16.8 6.55




















Fig. 3 The impact of LCIG therapy on the daily off-time duration
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Fig. 4 LCIG therapy cessation
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There were two patients with dopaminergic dysregula-
tion syndrome (one case of punding three months after
LCIG therapy initiation and one case of binge eating that
was present before and after LCIG therapy initiation).
Three patients had significant weight loss (6 kg within
3 months from LCIG therapy initiation and 15 kg in the
first year in one patient, 10 kg in the first month in the
second patient, and 11 kg in 1 year in the third patient).
Axonal neuropathy was present in six patients (one had
severe B12 deficiency, one had severe B6 deficiency, and
one had diabetes mellitus (DM); in four patients, the neu-
ropathy was hyperalgesic).
In three cases (2.65 %), LCIG therapy was not ceased
during nighttime, because of severe sleep disturbances or
severe motor symptoms during the night with oral
levodopa supplementation. There were 20 patients
(22.6 %) who were administered an extended-release
levodopa dose after the LCIG therapy had been stopped;
7 patients received a dopaminergic agonist at bedtime; 9
patients received an MAO inhibitor in the morning; and
6 patients received amantadine for persistent dyskinesia.
Of the 113 patients, 6 had psychiatric pathologies, 4
patients had associated dementia, and 6 patients had
depression; all of these disorders appeared before LCIG
therapy, and the patients received treatment for these
conditions.
The impact of LCIG therapy on non-motor symptoms
was also significant, with marked improvement in the
majority of them. Unfortunately, there was an inconsistent
screening for non-motor symptoms at the time of LCIG
therapy initiation, making also the results of their follow-up
less complete. However, of the symptoms that were noted,
the majority exhibited definite improvement.
Discussion
In Romania, LCIG therapy quickly became the most
optimal and readily available option for treating patients
with advanced PD. Our retrospective study is the first
observation of the Romanian experience regarding patients
who were diagnosed with advanced PD and who required
advanced therapy, thus receiving LCIG continuous infu-
sion therapy between 2009 and 30 September 2013.
Because additional patients were administered this
therapy after the cutoff date, the results regarding the
patient inclusion rate per year are only partial for the year
2013. Nevertheless, an increasing number of patients
receive LCIG infusion therapy every year, thus suggesting
that neurologists who work in outpatient clinics and in
primary and secondary care hospitals feel an increased
sense of confidence and have expertise in the use of LCIG
therapy.
According to the majority of studies (Nyholm et al.
2012), the low dropout rate is likely due to the already
proven efficacy of LCIG therapy. It has also been reported
(Nyholm et al. 2012) that there might be a correlation
between LCIG therapy duration and dropout incidence,
thus suggesting an increased likelihood of dropping out of
this treatment as the duration of the treatment increases.
Our observation revealed the following reasons for drop-
out: very advanced PD with dopaminergic adverse effects
and cognitive decline; patients becoming bedridden due to
non-related pathologies, thus making LCIG treatment
redundant; compliance issues; LCIG therapy-related com-
plications. Despite these exceptions, LCIG infusion therapy
resulted in homogeneous improvements in motor symptom
control (with ‘‘off’’ period reduction and dyskinesia daily
percentage reduction) and QoL, as reported by the patients.
The observed complications precipitated by the procedure
and pump system were, for the most part, due to anatomical
and physiological particularities of the patients (e.g., cas-
cade stomach, hiatal herniation, esophagitis, gastritis, and
peptic ulcer); in one case, we found a non-specific
inflammatory reaction of the duodenum that was resolved
after tube removal.
The recognition of non-motor PD symptoms was non-
homogeneous throughout the nine neurology centers in
Romania, likely because of a lack of a definite consensus in
this respect (Todorova et al. 2014), thus making it impos-
sible to accurately determine the impact of LCIG on non-
motor symptoms. Although motor symptoms have an
important influence on how the patient perceives his or her
QoL, non-motor symptoms are compelling runners-up,
sometimes being more important than the cardinal symp-
toms of PD in determining how the patient’s QoL is per-
ceived (Todorova et al. 2014). Given the constant
improvement in QoL, as demonstrated by the 10-point
VAS, it is safe to assume that levodopa-responsive non-
motor symptoms were also improved by LCIG therapy
(Antonini et al. 2015; Todorova and Ray Chaudhuri 2013).
However, there is a need for additional research to define a
consensus for non-motor PD symptom recognition and
treatment (Todorova et al. 2014; Rascol et al. 2011;
Antonini and Albin 2013).
Several studies have demonstrated a lack of difference
in the daily levodopa dose with LCIG and oral therapies
(Nyholm et al. 2005; Defer 2000), and other studies have
demonstrated a decrease in the daily levodopa dose after
LCIG (Nyholm et al. 2008). However, similar to a more
recent report (Devos 2009), our observation demonstrated
an increase in the mean daily levodopa intake. We also
noted a consequent decrease in the mean daily dyskinesia
percentage. This finding might indicate that patients tol-
erate higher daily doses of levodopa with obvious subse-
quent benefits (‘‘off’’ period reduction and better QoL)
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without having to pay the price of pulsatile levodopa
administration (oral therapy), which results in alternately
high and low levodopa concentration profiles, thus leading
to motor fluctuations (e.g., dyskinesia) (Devos 2009). The
small number of patients that required night pumps, night
oral extended-release levodopa tablets or adjuvant symp-
tomatic agents (agonists or MAO inhibitors) further high-
lights, as other studies have demonstrated (Nyholm et al.
2012), that LCIG is efficient.
In our group of patients, adverse events related to LCIG
therapy were rare. Indeed, the total number of AEs related
to the mode of administration of LCIG therapy (including
peri-procedural and immediate post-procedural complica-
tions of PEG/J placement, late complications of PEG/J and/
or infusion system complications) tend to decrease over
time. To our knowledge, this pattern is a result of the
decrease in the first two categories mentioned, which are
also the most common, considering that the adverse events
profile in PD patients resembles that of the PEG/J tube in
general (Fernandez et al. 2013). However, as other studies
(Nyholm 2012; Devos 2009; Zibetti et al. 2013a; Nyholm
et al. 2012; Honig et al. 2009) reported, adverse events
related strictly to the infusion system (or the late compli-
cations of PEG/J) are present in a significant number of
patients. Since in our group of patients an increasing
number of technical problems was observed even after the
cutoff date, we assume that an observation for a longer
period of time may have yielded slightly different results,
with respect to the number of LCIG therapy-related AEs.
Moreover, patients with more advanced stages of PD,
complicated with dementia, may be more prone to acci-
dental tube displacement. Besides, drug-related complica-
tions, such as weight loss and axonal neuropathy, may lead
to a variable degree of motor impairment, which could
have the same consequences (Devos 2009; Antonini et al.
2013; Mancini et al. 2014). Nevertheless, considering the
large number of patients who are currently receiving this
treatment worldwide, there is room for improving the
technical aspects of LCIG therapy and for minimizing
device-related complications.
Overall, LCIG therapy was definitely beneficial in terms
of controlling motor symptoms in our patients. Our
observation is congruent with published data from other
countries, thus confirming that LCIG therapy is an impor-
tant tool for treating patients with advanced Parkinson’s
disease.
The limitations of our study firstly lie in the shadow of
the study design, as retrospective data collection sometimes
revealed missing information. Secondly, since there was no
initially established consensus on non-motor symptoms
recording, data might be less revealing than we expected;
we also observed a high variability between centers, in this
respect. Furthermore, the relatively short observation time
period could be seen as another limitation, as a longer
follow-up would have probably revealed slightly different
results.
Conclusions
Our study demonstrated a homogeneous beneficial impact
of LCIG therapy in treating patients with advanced PD,
improving motor symptoms as well as their overall QoL, as
reported by the patients and their families. Because our
study was a retrospective observation, the impact of LCIG
therapy on non-motor symptoms was not homogeneously
recorded, and no statistical analysis could be performed. A
challenging task for future research is to demonstrate the
safety and the cost/benefit ratio of LCIG therapy in the long
term.
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